Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
Titel:
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
Auteur:
Gerber, David E. Socinski, Mark A. Neal, Joel W. Wakelee, Heather A. Shirai, Keisuke Sequist, Lecia V. Rosovsky, Rachel P. Lilenbaum, Rogerio C. Bastos, Bruno R. Huang, Chao Johnson, Melissa L. Hesketh, Paul J. Subramaniam, Deepa S. Dietrich, Martin F. Chai, Feng Wang, Yunxia Kazakin, Julia Schwartz, Brian Schiller, Joan H. Brahmer, Julie R. Kelly, Ronan J.